转移性肾癌的循环肿瘤分子标志物在靶向治疗中的研究进展(6)
[33] Gu L，Li H，Chen L，et al. MicroRNAs as prognostic molecular signatures in renal cell carcinoma：A systematic review and meta-analysis[J]. Oncotarget，2015，6(32)：32545-32560.
[34] Fedorko M，Stanik M，Iliev R，et al. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma[J]. Int J Mol Sci，2015， 16(10)：23382-23389.
[35] Zhao A，Li G，Peoc'h M，et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma[J]. Exp Mol Pathol，2013，94(1)：115-120.
[36] Gamez-Pozo A，Anton-Aparicio LM，Bayona C，et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients[J]. Neoplasia， 2012，14(12)：1144-1152.
[37] Gigante M，Pontrelli P，Herr W，et al. miR-29b and miR-198 overexpression in CD8+T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction[J]. J Transl Med，2016，14：84.
[38] Motzer RJ，Escudier B，McDermott DF，et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J].N Engl J Med，2015， 373(19)：1803-1813.
[39] McDermott DF，Sosman JA，Sznol M，et al. Atezolizumab，an Anti-Programmed Death-Ligand 1 Antibody，in Metastatic Renal Cell Carcinoma：Long-Term Safety，Clinical Activity，and Immune Correlates From a Phase Ia Study[J]. J Clin Oncol，2016，34(8)：833-842.
(收稿日期：2016-07-06) (任雨 石炳毅)
[34] Fedorko M，Stanik M，Iliev R，et al. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma[J]. Int J Mol Sci，2015， 16(10)：23382-23389.
[35] Zhao A，Li G，Peoc'h M，et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma[J]. Exp Mol Pathol，2013，94(1)：115-120.
[36] Gamez-Pozo A，Anton-Aparicio LM，Bayona C，et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients[J]. Neoplasia， 2012，14(12)：1144-1152.
[37] Gigante M，Pontrelli P，Herr W，et al. miR-29b and miR-198 overexpression in CD8+T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction[J]. J Transl Med，2016，14：84.
[38] Motzer RJ，Escudier B，McDermott DF，et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J].N Engl J Med，2015， 373(19)：1803-1813.
[39] McDermott DF，Sosman JA，Sznol M，et al. Atezolizumab，an Anti-Programmed Death-Ligand 1 Antibody，in Metastatic Renal Cell Carcinoma：Long-Term Safety，Clinical Activity，and Immune Correlates From a Phase Ia Study[J]. J Clin Oncol，2016，34(8)：833-842.
(收稿日期：2016-07-06) (任雨 石炳毅)